Piper Sandler Raises Price Target on AbbVie (ABBV) Amid Strong IBD Pipeline Progress

Pixabay/Public Domain

AbbVie Inc. (NYSE:ABBV) submitted 18 abstracts connected inflammatory bowel illnesses astatine the 2026 Digestive Disease Week Annual Meeting, which was held successful Chicago from May 2 to 5. The probe centered astir real-world grounds and semipermanent results for the company’s Crohn’s illness and ulcerative colitis therapies, SKYRIZI and RINVOQ.

The presumption featured 52-week follow-up results from the ASPIRE-CD study, which demonstrated that risankizumab-treated individuals with moderately to highly progressive Crohn’s illness had long-lasting improvements successful liquid stools, bowel urgency, and abdominal pain.

Piper Sandler stated that management’s pursuit of caller operation methods successful IBD is simply a affirmative development, considering the competitiveness of the IBD medicine improvement landscape. According to the firm, 1 origin that makes AbbVie Inc. (NYSE:ABBV) appealing is the assortment of R&D shots-on-goal that enactment beneath the radar of the wide concern market.

AbbVie Inc. (NYSE:ABBV) is simply a research-based biopharmaceutical institution that researches & develops, manufactures, commercializes, and sells medicines and therapies worldwide.

While we admit the imaginable of BAC arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.